JP6286696B2 - Drd2又はankk1のsnp遺伝子型に基づく抗精神病治療 - Google Patents
Drd2又はankk1のsnp遺伝子型に基づく抗精神病治療 Download PDFInfo
- Publication number
- JP6286696B2 JP6286696B2 JP2016002809A JP2016002809A JP6286696B2 JP 6286696 B2 JP6286696 B2 JP 6286696B2 JP 2016002809 A JP2016002809 A JP 2016002809A JP 2016002809 A JP2016002809 A JP 2016002809A JP 6286696 B2 JP6286696 B2 JP 6286696B2
- Authority
- JP
- Japan
- Prior art keywords
- iloperidone
- genotype
- individual
- snp
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100020756 D(2) dopamine receptor Human genes 0.000 title description 6
- 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 title description 6
- 230000000561 anti-psychotic effect Effects 0.000 title description 6
- 102100039182 Ankyrin repeat and protein kinase domain-containing protein 1 Human genes 0.000 title 1
- 101000889403 Homo sapiens Ankyrin repeat and protein kinase domain-containing protein 1 Proteins 0.000 title 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 61
- 229960003162 iloperidone Drugs 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 20
- 208000028017 Psychotic disease Diseases 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 102220110850 rs6275 Human genes 0.000 claims description 4
- 108700028369 Alleles Proteins 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 201000000980 schizophrenia Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000000698 schizophrenic effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 102000008102 Ankyrins Human genes 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000009522 phase III clinical trial Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229960000607 ziprasidone Drugs 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- JRZHFUQNEFFGQF-UHFFFAOYSA-N 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-2,5-dihydroxyphenyl]ethanone Chemical compound C1=C(O)C(C(=O)C)=CC(O)=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 JRZHFUQNEFFGQF-UHFFFAOYSA-N 0.000 description 1
- WGMMOJQKFITEFG-UHFFFAOYSA-N 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-2-hydroxy-5-methoxyphenyl]ethanone Chemical compound COC1=CC(C(C)=O)=C(O)C=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 WGMMOJQKFITEFG-UHFFFAOYSA-N 0.000 description 1
- JRAOALKNNYGKLE-UHFFFAOYSA-N 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-hydroxyphenyl]ethanone Chemical compound OC1=CC(C(=O)C)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 JRAOALKNNYGKLE-UHFFFAOYSA-N 0.000 description 1
- BGCPETUXPSZMBH-UHFFFAOYSA-N 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]-2-hydroxyethanone Chemical compound COC1=CC(C(=O)CO)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 BGCPETUXPSZMBH-UHFFFAOYSA-N 0.000 description 1
- SBKZGLWZGZQVHA-UHFFFAOYSA-N 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanol Chemical compound COC1=CC(C(C)O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 SBKZGLWZGZQVHA-UHFFFAOYSA-N 0.000 description 1
- SABFAXRMOAQYKG-UHFFFAOYSA-N 2-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-5-(1-hydroxyethyl)phenol Chemical compound OC1=CC(C(O)C)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 SABFAXRMOAQYKG-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- VRBRWIBMEPFSLK-UHFFFAOYSA-N C(CC)OC=1C(=C(C=C(C1)OC)C(O)C)O Chemical compound C(CC)OC=1C(=C(C=C(C1)OC)C(O)C)O VRBRWIBMEPFSLK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- -1 sachet Substances 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本出願は、2009年5月15日に出願された同時係属中の米国仮特許出願第61/178,934号の利益を主張し、これは、参照により本明細書中に組み込まれる。
Claims (4)
- 個体における少なくとも1つの精神病症状の治療でのイロペリドン使用の有効性の予測を補助する方法であって、rs1800497一塩基多型(SNP)における前記個体の遺伝子型を決定するステップを含み、
前記予測は、rs1800497 SNP座位における前記個体の遺伝子型がA2A2である場合に、イロペリドンによる前記個体の治療が有効であると予測することを含む、方法。 - rs1799978、rs1799732、rs2283265、rs1076560、及びrs6275からなる群から選択される少なくとも1つの追加のSNPにおいて前記個体の遺伝子型を決定するステップをさらに含み、
前記予測は、前記少なくとも1つの追加のSNP座位における前記個体の遺伝子型がイロペリドンの相対的に高い有効性と関連する場合に、イロペリドンによる前記個体の治療が有効であると予測することをさらに含む、請求項1に記載の方法。 - 前記少なくとも1つの追加のSNPがrs2283265であり、且つイロペリドンの相対的に高い有効性と関連する遺伝子型が非G/Tである、請求項2に記載の方法。
- 前記少なくとも1つの追加のSNPがrs1076560であり、且つイロペリドンの相対的に高い有効性と関連する遺伝子型が非G/Tである、請求項2に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17893409P | 2009-05-15 | 2009-05-15 | |
US61/178,934 | 2009-05-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012511063A Division JP2012526562A (ja) | 2009-05-15 | 2010-05-15 | Drd2又はankk1のsnp遺伝子型に基づく抗精神病治療 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017196243A Division JP6528158B2 (ja) | 2009-05-15 | 2017-10-06 | Drd2又はankk1のsnp遺伝子型に基づく抗精神病治療 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016116524A JP2016116524A (ja) | 2016-06-30 |
JP6286696B2 true JP6286696B2 (ja) | 2018-03-07 |
Family
ID=42555548
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012511063A Pending JP2012526562A (ja) | 2009-05-15 | 2010-05-15 | Drd2又はankk1のsnp遺伝子型に基づく抗精神病治療 |
JP2016002809A Active JP6286696B2 (ja) | 2009-05-15 | 2016-01-08 | Drd2又はankk1のsnp遺伝子型に基づく抗精神病治療 |
JP2017196243A Active JP6528158B2 (ja) | 2009-05-15 | 2017-10-06 | Drd2又はankk1のsnp遺伝子型に基づく抗精神病治療 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012511063A Pending JP2012526562A (ja) | 2009-05-15 | 2010-05-15 | Drd2又はankk1のsnp遺伝子型に基づく抗精神病治療 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017196243A Active JP6528158B2 (ja) | 2009-05-15 | 2017-10-06 | Drd2又はankk1のsnp遺伝子型に基づく抗精神病治療 |
Country Status (7)
Country | Link |
---|---|
US (3) | US9057104B2 (ja) |
EP (1) | EP2430183B1 (ja) |
JP (3) | JP2012526562A (ja) |
CA (1) | CA2760474C (ja) |
ES (1) | ES2533091T3 (ja) |
SM (1) | SMT201500064B (ja) |
WO (1) | WO2010132866A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140255930A1 (en) * | 2011-09-08 | 2014-09-11 | Ohio State Innovation Foundation | Materials and Methods Related to Dopamine Dysregulation Disorders |
AU2013232014B2 (en) | 2012-03-14 | 2016-06-16 | Vanda Pharmaceuticals Inc. | An iloperidone metabolite for use in the treatment of psychiatric disorders |
CN107249586A (zh) * | 2015-02-17 | 2017-10-13 | 万达制药公司 | 用于治疗精神分裂症的伊潘立酮 |
CN106434678A (zh) * | 2016-08-30 | 2017-02-22 | 张建华 | 一个青春型精神分裂症关联基因 |
JP6935079B2 (ja) * | 2017-05-09 | 2021-09-15 | 国立大学法人千葉大学 | 機能的snpの組合せ解析 |
US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
WO2020111169A1 (ja) * | 2018-11-28 | 2020-06-04 | 国立大学法人千葉大学 | 多因子遺伝疾患の遺伝子検査法、及び検査キット |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005512576A (ja) * | 2001-12-10 | 2005-05-12 | ノバルティス アクチエンゲゼルシャフト | Cntf遺伝子多型に基づく、精神病および統合失調症の処置方法 |
AU2004258147B2 (en) | 2003-07-08 | 2009-04-30 | State Of Queensland Acting Through Queensland Health | Genetic marker of response to atypical antipsychotics and antidepressants and methods for use thereof |
CA2582022C (en) * | 2004-09-30 | 2021-05-18 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
ES2681240T3 (es) * | 2007-05-18 | 2018-09-12 | Vanda Pharmaceuticals Inc. | Marcadores genéticos de eficacia de iloperidona en el tratamiento de síntomas psicóticos |
CA2699786C (en) * | 2007-09-10 | 2019-08-13 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on snp genotype |
-
2010
- 2010-05-15 US US13/319,430 patent/US9057104B2/en active Active
- 2010-05-15 ES ES10719224.7T patent/ES2533091T3/es active Active
- 2010-05-15 JP JP2012511063A patent/JP2012526562A/ja active Pending
- 2010-05-15 EP EP10719224.7A patent/EP2430183B1/en active Active
- 2010-05-15 WO PCT/US2010/035045 patent/WO2010132866A1/en active Application Filing
- 2010-05-15 CA CA2760474A patent/CA2760474C/en active Active
-
2015
- 2015-03-16 SM SM201500064T patent/SMT201500064B/xx unknown
- 2015-05-08 US US14/707,477 patent/US9243295B2/en active Active
- 2015-12-12 US US14/967,276 patent/US9408839B2/en active Active
-
2016
- 2016-01-08 JP JP2016002809A patent/JP6286696B2/ja active Active
-
2017
- 2017-10-06 JP JP2017196243A patent/JP6528158B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2010132866A1 (en) | 2010-11-18 |
JP2016116524A (ja) | 2016-06-30 |
US9243295B2 (en) | 2016-01-26 |
US9057104B2 (en) | 2015-06-16 |
JP6528158B2 (ja) | 2019-06-12 |
SMT201500064B (it) | 2015-07-09 |
CA2760474A1 (en) | 2010-11-18 |
EP2430183B1 (en) | 2014-12-17 |
US20160166561A1 (en) | 2016-06-16 |
JP2012526562A (ja) | 2012-11-01 |
ES2533091T3 (es) | 2015-04-07 |
US20120053207A1 (en) | 2012-03-01 |
US9408839B2 (en) | 2016-08-09 |
CA2760474C (en) | 2020-08-18 |
EP2430183A1 (en) | 2012-03-21 |
JP2018046829A (ja) | 2018-03-29 |
US20150315648A1 (en) | 2015-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6286696B2 (ja) | Drd2又はankk1のsnp遺伝子型に基づく抗精神病治療 | |
JP6815372B2 (ja) | 疾患危険因子を同定する方法 | |
JP5535914B2 (ja) | Snp遺伝子型に基づく抗精神病薬治療 | |
US10098893B2 (en) | Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457 | |
JP6108633B2 (ja) | Kcnq1遺伝子の多型に基づいた治療方法 | |
JP2005507261A (ja) | Tcf1遺伝子における多型に基づく糖尿病および関連状態の治療方法 | |
Domschke et al. | Monoamine oxidase A variant influences antidepressant treatment response in female patients with major depression | |
JP2017528483A (ja) | Val66Met(SNP rs6265)遺伝子型特異的投薬レジメン及びうつ病の治療のための方法 | |
JP2012507297A (ja) | Erbb4遺伝子の多型に基づく精神病及び統合失調症の治療法 | |
EP2841068A2 (en) | Crhr1 antagonists for use in the treatment of patients having crh overactivity | |
TW201326399A (zh) | 用於預測對格拉替雷(glatiramer)醋酸鹽之臨床反應之單核苷酸多型性之判定 | |
EP4005570A1 (en) | Use of pridopidine for treating rett syndrome | |
Kurose et al. | Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression | |
JP5692872B2 (ja) | Bai遺伝子の配列又はその産物に基づいてqt延長に対する素因を予測する方法 | |
JP5881597B2 (ja) | Qt延長に対する素因を予測する方法 | |
US11214827B2 (en) | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone | |
US11607408B2 (en) | Method of treatment of schizophrenia | |
CA2540760C (en) | Use of genetic polymorphisms to predict drug-induced hepatotoxicity | |
EP2594649A1 (en) | A method and a kit to predict response to antidepressant treatment | |
RU2540475C1 (ru) | Способ лечения пациента с гипертрофической кардиомиопатией |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161108 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170410 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171002 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20171024 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180111 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6286696 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |